Literature DB >> 28058524

Determination of residual dimethylsulfoxide in cryopreserved cardiovascular allografts.

R Díaz Rodríguez1, B Van Hoeck2, S De Gelas3, F Blancke3, R Ngakam2, K Bogaerts4,5, R Jashari2.   

Abstract

Dimethylsulfoxide (DMSO) is a solvent which protects the structure of allografts during the cryopreservation and thawing process. However, several toxic effects of DMSO in patients after transplantation of cryopreserved allografts have been described. The aim of this study is to determine the residual DMSO in the cardiovascular allografts after thawing and preparation of cryopreserved allografts for clinical application following guidelines of the European Pharmacopoeia for DMSO detection. Four types of EHB allografts (aortic valve-AV, pulmonary valve-PV, descending thoracic aorta-DA, and femoral artery-FA) are cryopreserved using as cryoprotecting solution a 10% of DMSO in medium 199. Sampling is carried out after thawing, after DMSO dilution and after delay of 30 min from final dilution (estimated delay until allograft implantation). After progressive thawing in sterile water bath at 37-42 °C (duration of about 20 min), DMSO dilution is carried out by adding consecutively 33, 66 and 200 mL of saline. Finally, tissues are transferred into 200 mL of a new physiologic solution. Allograft samples are analysed for determination of the residual DSMO concentration using a validated Gas Chromatography analysis. Femoral arteries showed the most important DMSO reduction after the estimated delay: 92.97% of decrease in the cryoprotectant final amount while a final reduction of 72.30, 72.04 and 76.29% in DMSO content for AV, PV and DA, was found, respectively. The residual DMSO in the allografts at the moment of implantation represents a final dose of 1.95, 1.06, 1.74 and 0.26 mg kg-1 in AV, PV, DA and FA, respectively, for men, and 2.43, 1.33, 2.17 and 0.33 mg kg-1 for same tissues for women (average weight of 75 kg in men, and 60 kg in women). These results are seriously below the maximum recommended dose of 1 g DMSO kg-1 (Regan et al. in Transfusion 50:2670-2675, 2010) of weight of the patient guaranteeing the safety and quality of allografts.

Entities:  

Keywords:  Cardiovascular allografts; Cryopreservation; Dimethylsulfoxide

Mesh:

Substances:

Year:  2017        PMID: 28058524     DOI: 10.1007/s10561-016-9607-0

Source DB:  PubMed          Journal:  Cell Tissue Bank        ISSN: 1389-9333            Impact factor:   1.522


  3 in total

1.  The cryoprotectant trehalose could inhibit ERS-induced apoptosis by activating autophagy in cryoprotected rat valves.

Authors:  Hongyan Wu; Qing Chang
Journal:  PLoS One       Date:  2018-03-09       Impact factor: 3.240

2.  Transplantation of cryopreserved human heart valves in Europe: 30 years of banking in Brussels and future perspectives.

Authors:  Ramadan Jashari
Journal:  Cell Tissue Bank       Date:  2021-02-02       Impact factor: 1.522

3.  Analysis of Cryopreservation Protocols and Their Harmful Effects on the Endothelial Integrity of Human Corneas.

Authors:  Silvia Rodríguez-Fernández; Marcelino Álvarez-Portela; Esther Rendal-Vázquez; María Piñeiro-Ramil; Clara Sanjurjo-Rodríguez; Rocío Castro-Viñuelas; Jacinto Sánchez-Ibáñez; Isaac Fuentes-Boquete; Silvia Díaz-Prado
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.